Claims for Patent: 9,623,118

Summary for Patent: 9,623,118

Title:	Multi-arm linker constructs for treating pathological blood clots
Abstract:	The present disclosure provides various molecular constructs having a targeting element and an effector element. Methods for treating various diseases using such molecular constructs are also disclosed.
Inventor(s):	Chang; Tse-Wen (Taipei, TW), Chu; Hsing-Mao (Taipei, TW), Lin; Chun-Yu (Taipei, TW)
Assignee:
Application Number:	15/212,298
Patent Claims:	1. A linker unit comprising a center core, a plurality of linking arms, a plurality of first elements, and optionally a coupling arm, wherein the center core comprises, (1) a first polypeptide comprising a plurality of lysine (K) residues, wherein each K residue and its next K residue are separated by a filler sequence comprising glycine (G) and serine (S) residues, and the number of K residues ranges from 2 to 15; or (2) a second polypeptide comprising the sequence of (X.sub.aa-K).sub.n, where X.sub.aa is a PEGylated amino acid having 2 to 12 repeats of ethylene glycol (EG) unit, and n is an integer from 2 to 15; the plurality of linking arms are respectively linked to the K residues of the center core; the plurality of first elements are respectively linked to the plurality of linking arms via forming an amide bond therebetween, or via thiol-maleimide reaction, copper catalyzed azide-alkyne cycloaddition (CuAAC) reaction, strained-promoted azide-alkyne click chemistry (SPAAC) reaction, or inverse electron demand Diels-Alder (iEDDA) reaction, wherein each of the first elements is an single-chain variable fragment (scFv) specific for fibrin; and the amino acid residue at the N- or C-terminus of the center core has the azide or the alkyne group; or the amino acid residue at the N- or C-terminus of the center core is a cysteine residue, and the thiol group of the cysteine residue is linked with the coupling arm having an azide, an alkyne, a tetrazine, a cyclooctene, or a cyclooctyne group at the free terminus of the coupling arm, wherein, when the plurality of first elements are respectively linked to the plurality of linking arms via CuAAC or SPAAC reaction, then the amino acid residue at the N- or C-terminus of the center core is a cysteine residue, and the free terminus of the coupling arm is the tetrazine or the cyclooctene group; or when the plurality of first elements are respectively linked to the plurality of linking arms via iEDDA reaction, then the amino acid residue at the N- or C-terminus of the center core has the azide or the alkyne group, or the amino acid residue at the N- or C-terminus of the center core is a cysteine residue, and the free terminus of the coupling arm is the azide, the alkyne, or the cyclooctyne group. 2. The linker unit of claim 1, wherein the filler sequence has one of the sequences selected from the group consisting of GS, GGS, GSG, or one of SEQ ID NOs: 1-16. 3. The linker unit of claim 1, wherein the first polypeptide comprises 2-15 units of the sequence of G.sub.1-5SK. 4. The linker unit of claim 3, wherein the first polypeptide comprises the sequence of (GSK).sub.2-15. 5. The linker unit of claim 1, wherein each of the linking arms is a PEG chain having 2-20 repeats of EG units. 6. The linker unit of claim 1, wherein the coupling arm is a PEG chain having 2-12 repeats of EG units. 7. The linker unit of claim 1, wherein the amino acid residue having the azide group is L-azidohomoalanine (AHA), 4-azido-L-phenylalanine, 4-azido-D-phenylalanine, 3-azido-L-alanine, 3-azido-D-alanine, 4-azido-L-homoalanine, 4-azido-D-homoalanine, 5-azido-L-ornithine, 5-azido-d-ornithine, 6-azido-L-lysine, or 6-azido-D-lysine. 8. The linker unit of claim 1, wherein the amino acid residue having the alkyne group is L-homopropargylglycine (L-HPG), D-homopropargylglycine (D-HPG), or beta-homopropargylglycine (.beta.-HPG). 9. The linker unit of claim 1, wherein the cyclooctene group is trans-cyclooctene (TCO); and the cyclooctyne group is dibenzocyclooctyne (DBCO), difluorinated cyclooctyne (DIFO), bicyclononyne (BCN), or dibenzocyclooctyne (DICO). 10. The linker unit of claim 1, wherein the tetrazine group is 1,2,3,4-tetrazine, 1,2,3,5-tetrazine or 1,2,4,5-tetrazine, or derivatives thereof. 11. The linker unit of claim 1, further comprising a second element that is linked to the center core via any of the following reactions, CuAAC reaction occurred between the azide or alkyne group and the second element; SPAAC reaction occurred between the azide or cyclooctyne group and the second element; and iEDDA reaction occurred between the cyclooctene group or tetrazine group and the second element. 12. The linker unit of claim 11, wherein the second element is a tissue plasminogen activator or an inhibitor of Factor Xa or thrombin. 13. The linker unit of claim 12, wherein the tissue plasminogen activator is alteplase, reteplase, tenecteplase, or lanoteplase. 14. The linker unit of claim 12, wherein the inhibitor of Factor Xa is apixaban, edoxaban, or rivaroxaban; and the inhibitor of thrombin is argatroban or melagatran. 15. The linker unit of claim 11, wherein the second element is linked to the azide or alkyne group of the N- or C-terminal amino acid residues of the center core via CuAAC reaction. 16. The linker unit of claim 15, further comprising a third element that is linked to the coupling arm via iEDDA reaction. 17. The linker unit of claim 16, wherein the third element is a long PEG chain having a molecular weight of about 20,000 to 50,000 Daltons. 18. The linker unit of claim 11, wherein the second element is linked to the azide group of the N- or C-terminal amino acid residues of the center core via SPAAC reaction. 19. The linker unit of claim 18, further comprising a third element that is linked to the coupling arm via iEDDA reaction. 20. The linker unit of claim 19, wherein the third element is a long PEG chain having a molecular weight of about 20,000 to 50,000 Daltons. 21. A method for preventing the formation of blood clot in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the linker unit of claim 12. 22. The method of claim 21, wherein the second element is the inhibitor of Factor Xa or thrombin. 23. The method of claim 22, wherein, the inhibitor of Factor Xa is apixaban, edoxaban, or rivaroxaban; and the inhibitor of thrombin is argatroban or melagatran. 24. A method for treating thrombosis in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the linker unit of claim 12. 25. The method of claim 24, wherein the second element is the tissue plasminogen activator. 26. The method claim 24, wherein the tissue plasminogen activator is alteplase, reteplase, tenecteplase, or lanoteplase.

Details for Patent 9,623,118

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	ACTIVASE	alteplase	For Injection	103172	11/13/1987		2039-02-26
Genentech, Inc.	CATHFLO ACTIVASE	alteplase	For Injection	103172	09/04/2001		2039-02-26
Chiesi Usa, Inc.	RETAVASE	reteplase	For Injection	103786	10/30/1996		2039-02-26